Investor Resources

Exclusive information for InSitu Biologics Shareholders

A Letter from our CEO:

Hello,

Thank you for investing in our company. We are proud of where we’ve been and excited about where we’re going. This page along with Updates Page should serve as a good resource for you to find out what’s happening. And as always please feel free to send me an email.

Thank you again for your investment.

Jim Segermark

jim@insitubiologics.com

Join the community and stay connected on Social Media:

FacebookLinkedInTwitterInstagram

Create a New Account with Computershare

As a shareholder you can view and manage your shares via Computershare. If you do not already have a Computershare account, please create one following the steps in this guide:

powered by Typeform

View Previous Q&A Webinar & Conference Call Recordings

Offered several times per month, view one of our past Q&A webinars with CEO Jim Segermark.
Register for an upcoming webinar or conference call

August 15 Q&A Webcast: The Significance of AnestaGel in Pre-Clinical Studies
CEO Jim Segermark hosts a conference call with discussion about our Matrix BioHydrogel, and our Pre-Clinical stage, long-lasting and long-acting non-opiate painkiller, AnestaGel™& AniGel™ and addresses frequently asked questions.

Special guest Dr. Jake Hutchins will joins the webcast to discuss the significance of AnestaGel in Pre-Clinical studies.

August 11 Q&A Webcast
CEO Jim Segermark hosts a conference call with discussion about our Matrix BioHydrogel, and our pre-clinical stage, long-lasting and long-acting non-opiate painkiller, AnestaGel™& AniGel™ and addresses frequently asked questions.

August 6 Q&A Webcast
CEO Jim Segermark hosts a conference call with discussion about our Matrix BioHydrogel, and our pre-clinical stage, long-lasting and long-acting non-opiate painkiller, AnestaGel™& AniGel™ and addresses frequently asked questions.

August 4 Q&A Webcast
CEO Jim Segermark hosts a conference call with discussion about our Matrix BioHydrogel, and our pre-clinical stage, long-lasting and long-acting non-opiate painkiller, AnestaGel™& AniGel™ and addresses frequently asked questions.

July 31 Q&A Webcast
CEO Jim Segermark hosts a conference call with discussion about our Matrix BioHydrogel, and our pre-clinical stage, long-lasting and long-acting non-opiate painkiller, AnestaGel™& AniGel™ and addresses frequently asked questions.

July 28 Q&A Webcast: Fractures
Special guest Dr. Dan Sipple joins CEO Jim Segermark for a discussion with Q&A on the standard of care for fractures.

July 25 CEO Conference Call
CEO Jim Segermark hosts a conference call with discussion about our Matrix BioHydrogel, and our pre-clinical stage, long-lasting and long-acting non-opiate painkiller, AnestaGel™& AniGel™ and addresses frequently asked questions.

July 23 Q&A Webcast: Hot Topics in Pain Management
Special Guest Dr. Jake Hutchins joins CEO Jim Segermark for a wide ranging discussion with Q&A on state of the art in Post-Operative Pain Control.

July 17 Q&A Webcast
CEO Jim Segermark hosts a webinar with discussion about our Matrix BioHydrogel, and our pre-clinical stage, long-lasting and long-acting non-opiate painkiller, AnestaGel™& AniGel™ and addresses frequently asked questions.

July 12 CEO Conference Call
CEO Jim Segermark hosts a conference call with discussion about our Matrix BioHydrogel, and our pre-clinical stage, long-lasting and long-acting non-opiate painkiller, AnestaGel™& AniGel™ and addresses frequently asked questions.

July 9 Q&A
CEO Jim Segermark hosts a Q&A with discussion about our Matrix BioHydrogel, and our pre-clinical stage, long-lasting and long-acting non-opiate painkiller, AnestaGel™& AniGel™.

June 26 Q&A
CEO Jim Segermark hosts a Q&A with discussion about our Matrix BioHydrogel, and our pre-clinical stage, long-lasting and long-acting non-opiate painkiller, AnestaGel™.

June 12 Q&A
CEO Jim Segermark hosts a Q&A with discussion about our Matrix BioHydrogel, and our pre-clinical stage, long-lasting and long-acting non-opiate painkiller, AnestaGel™.

June 11 
CEO Jim Segermark & Veterinarian Stacie Lipinski discuss Current Standards in Spay & Neuter Pain Management.

May 28, 2019 Q&A
CEO Jim Segermark hosts a Q&A with discussion about our Matrix BioHydrogel, and our pre-clinical stage, long-lasting and long-acting non-opiate painkiller, AnestaGel™.